An update on the malignant hyperthermia syndrome
- PMID: 7710242
An update on the malignant hyperthermia syndrome
Abstract
Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle. In humans, MH is inherited in an autosomal dominant fashion; in swine, the principal model for MH, it is in a recessive fashion. Those with MH susceptibility usually are asymptomatic except in the presence of certain "triggering" anaesthetic agents such as isoflurane, enflurane and the muscle relaxant succinylcholine. Upon such exposure hypermetabolism, increased CO2 production, acidosis, muscle rigidity, rhabdomyolysis and hyperthermia occur. Untreated, death may result in 70% of patients. With prompt diagnosis and treatment with dantrolene sodium, the mortality is less than 10%. The overall incidence of MH is low (perhaps 1:50,000 anaesthetics), but it is more common in children. Children also display a paradoxical increase in jaw muscle tone to succinylcholine which often presages MH, but confusing clinically, may also be a normal response to succinylcholine. The pathophysiology of MH centres around a defect in calcium flux in skeletal muscle. A specific base pair change in the gene that codes for the ryanodine receptor calcium channel in muscle has been demonstrated in susceptible swine, but occurs rarely in humans. It is hoped that the understanding of the molecular genetics of MH will lead to a simpler diagnostic test than is currently available, and enhance our understanding of MH and its relation to other myopathies.
Similar articles
-
Malignant hyperthermia.Orphanet J Rare Dis. 2007 Apr 24;2:21. doi: 10.1186/1750-1172-2-21. Orphanet J Rare Dis. 2007. PMID: 17456235 Free PMC article. Review.
-
Malignant hyperthermia.Postgrad Med J. 1998 Jan;74(867):11-7. doi: 10.1136/pgmj.74.867.11. Postgrad Med J. 1998. PMID: 9538480 Free PMC article. Review.
-
Malignant hyperthermia.Lancet. 1998 Oct 3;352(9134):1131-6. doi: 10.1016/S0140-6736(98)03078-5. Lancet. 1998. PMID: 9798607 Review.
-
Malignant hyperthermia.J Craniofac Surg. 2003 Sep;14(5):800-2. doi: 10.1097/00001665-200309000-00039. J Craniofac Surg. 2003. PMID: 14501352
-
[Pharmacological Treatment of Malignant Hyperthermia: Update 2019].Anasthesiol Intensivmed Notfallmed Schmerzther. 2019 Sep;54(9):549-558. doi: 10.1055/a-0725-7577. Epub 2019 Sep 16. Anasthesiol Intensivmed Notfallmed Schmerzther. 2019. PMID: 31525788 German.
Cited by
-
Malignant Hyperthermia in PICU-From Diagnosis to Treatment in the Light of Up-to-Date Knowledge.Children (Basel). 2022 Nov 4;9(11):1692. doi: 10.3390/children9111692. Children (Basel). 2022. PMID: 36360420 Free PMC article. Review.
-
Development of Ryanodine Receptor (RyR) Inhibitors for Skeletal Muscle and Heart Diseases.Juntendo Iji Zasshi. 2023 Apr 26;69(3):180-187. doi: 10.14789/jmj.JMJ22-0045-R. eCollection 2023. Juntendo Iji Zasshi. 2023. PMID: 38855953 Free PMC article.
-
Personalized pediatric anesthesia and pain management: problem-based review.Pharmacogenomics. 2020 Jan;21(1):55-73. doi: 10.2217/pgs-2019-0108. Pharmacogenomics. 2020. PMID: 31849281 Free PMC article. Review.
-
Sudden death due to malignant hyperthermia with a mutation of RYR1: autopsy, morphology and genetic analysis.Forensic Sci Med Pathol. 2017 Dec;13(4):444-449. doi: 10.1007/s12024-017-9925-y. Epub 2017 Nov 4. Forensic Sci Med Pathol. 2017. PMID: 29101530
-
Increased rate of complications in myasthenia gravis patients following hip and knee arthroplasty: a nationwide database study in the PearlDiver Database on 257,707 patients.Acta Orthop. 2021 Apr;92(2):176-181. doi: 10.1080/17453674.2020.1865031. Epub 2021 Jan 4. Acta Orthop. 2021. PMID: 33390062 Free PMC article.